{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:43:12Z","timestamp":1792698192357,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi241371-4\"><jats:title>Importance<\/jats:title><jats:p>For patients with atrial fibrillation, clinicians often prescribe antiplatelet therapy rather than oral anticoagulation, which may be related to a concern that direct oral anticoagulants (DOACs) are associated with a higher risk of intracranial bleeding, despite being less effective for stroke prevention.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241371-5\"><jats:title>Objective<\/jats:title><jats:p>To determine whether DOAC therapy, compared with single-agent antiplatelet therapy, was associated with an increased risk of intracranial and major hemorrhage.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241371-6\"><jats:title>Data Sources<\/jats:title><jats:p>A systematic search of PubMed and Embase databases from inception to February 7, 2024, was performed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241371-7\"><jats:title>Study Selection<\/jats:title><jats:p>Randomized clinical trials that compared DOAC therapy with single-agent antiplatelet therapies were included. Trials with active follow-up of less than 30 days or a sample size less than 200 were excluded.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241371-8\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data were extracted independently by 2 researchers. A random-effects meta-analysis model was used to report pooled treatment effects and 95% CIs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241371-9\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was occurrence of intracranial hemorrhage.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241371-10\"><jats:title>Results<\/jats:title><jats:p>A total of 9 randomized clinical trials were included (45\u202f494 participants). DOAC therapy was not associated with significantly higher odds of intracranial hemorrhage compared with antiplatelet therapy (0.55% vs 0.48% over a mean trial follow-up of 17.1 months; odds ratio [OR], 1.15; 95% CI, 0.71-1.88), but there was heterogeneity among trials (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200953.7%). In an analysis by DOAC agent, the respective estimates for intracranial hemorrhage risk were as follows: rivaroxaban, OR, 2.09 (95% CI, 1.20-3.64); dabigatran, OR, 1.00 (95% CI, 0.61-1.64); and apixaban, OR, 0.72 (95% CI, 0.44-1.17). Overall, DOAC therapy was associated with higher odds of major hemorrhage compared with antiplatelet therapy (2.41% vs 1.76% over a mean trial follow-up of 15.5 months; OR, 1.39; 95% CI, 1.07-1.80), with the following estimates by agent: rivaroxaban, OR, 1.91 (95% CI, 1.22-3.00); dabigatran; OR, 1.21 (95% CI, 0.86-1.69); and apixaban, OR, 1.09 (95% CI, 0.73-1.63).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi241371-11\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this systematic review and meta-analysis, DOAC therapy was not associated with a significantly higher risk of intracranial hemorrhage compared with antiplatelet therapy, but was associated with a higher risk of major hemorrhage. These findings support the safety of DOAC compared with antiplatelet therapy with respect to risk of ICH and reinforce adherence with current atrial fibrillation guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.49017","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:00:45Z","timestamp":1733328045000},"page":"e2449017","source":"Crossref","is-referenced-by-count":32,"title":["Risk of Intracranial Hemorrhage Associated With Direct Oral Anticoagulation vs Antiplatelet Therapy"],"prefix":"10.1001","volume":"7","author":[{"given":"Mark","family":"Coyle","sequence":"first","affiliation":[{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"Department of Medicine, Galway University Hospital, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lynch","sequence":"additional","affiliation":[{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"Department of Medicine, Galway University Hospital, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meave","family":"Higgins","sequence":"additional","affiliation":[{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"Department of Medicine, Galway University Hospital, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Costello","sequence":"additional","affiliation":[{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"Department of Medicine, Galway University Hospital, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Judge","sequence":"additional","affiliation":[{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"Department of Medicine, Galway University Hospital, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"Department of Medicine, Galway University Hospital, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Reddin","sequence":"additional","affiliation":[{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"Department of Medicine, Galway University Hospital, Galway, Ireland"},{"name":"Wellcome Trust Health Research Board, Irish Clinical Academic Training, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"1","key":"zoi241371r1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"zoi241371r2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"zoi241371r3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1016\/j.jacc.2016.03.581","article-title":"Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke.","volume":"67","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"zoi241371r4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436?864 patients with atrial fibrillation in community practice, 2011 to 2020.","volume":"11","author":"Navar","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"zoi241371r5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/ehjcvp\/pvab044","article-title":"Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials.","volume":"8","author":"Benz","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"zoi241371r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9638","article-title":"Patients and their physician\u2019s perspectives about oral anticoagulation in patients with atrial fibrillation not receiving an anticoagulant.","volume":"6","author":"Cannon","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10191","key":"zoi241371r7","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1016\/S0140-6736(19)30840-2","article-title":"Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial.","volume":"393","author":"Al-Shahi Salman","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"zoi241371r8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi241371r9","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/jth.13697","article-title":"Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.","volume":"15","author":"Melkonian","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"4","key":"zoi241371r11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi241371r12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan: a web and mobile app for systematic reviews.","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"13","key":"zoi241371r13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism.","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi241371r14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"zoi241371r15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"14","key":"zoi241371r16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease.","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi241371r17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation.","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi241371r18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source.","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi241371r19","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source.","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi241371r20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi241371r21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial.","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"zoi241371r22","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300235","article-title":"Apixaban versus aspirin for embolic stroke of undetermined source.","volume":"3","author":"Geisler","year":"2024","journal-title":"NEJM Evid"},{"issue":"4","key":"zoi241371r23","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1161\/STROKEAHA.119.027569","article-title":"Dabigatran treatment of acute noncardioembolic ischemic stroke.","volume":"51","author":"Butcher","year":"2020","journal-title":"Stroke"},{"issue":"9921","key":"zoi241371r24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"zoi241371r25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12959-021-00322-6","article-title":"Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis.","volume":"19","author":"Chen","year":"2021","journal-title":"Thromb J"},{"key":"zoi241371r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2023.100284","article-title":"Reimbursement and use of oral anticoagulants during 2014-2022: a register-based study.","volume":"11","author":"Aarnio","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"7323","key":"zoi241371r27","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"key":"zoi241371r28","doi-asserted-by":"publisher","first-page":"k2505","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.","volume":"362","author":"Vinogradova","year":"2018","journal-title":"BMJ"},{"issue":"10","key":"zoi241371r29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi241371r30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi241371r31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40271-013-0020-5","article-title":"Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.","volume":"6","author":"Lalibert\u00e9","year":"2013","journal-title":"Patient"},{"issue":"2","key":"zoi241371r32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40801-021-00289-w","article-title":"Adherence and persistence with once-daily vs twice-daily direct oral anticoagulants among patients with atrial fibrillation: real-world analyses from the Netherlands, Italy and Germany.","volume":"9","author":"Smits","year":"2022","journal-title":"Drugs Real World Outcomes"},{"issue":"10","key":"zoi241371r33","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1111\/j.1538-7836.2010.04016.x","article-title":"Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy.","volume":"8","author":"Linkins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"zoi241371r10","unstructured":"Higgins? JPT, Thomas? J, Chandler? J, , eds. Cochrane Handbook for Systematic Reviews of Interventions, version 6.4. August 2023. Accessed October 28, 2024. http:\/\/www.training.cochrane.org\/handbook"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2827224\/coyle_2024_oi_241371_1732143041.65966.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:00:48Z","timestamp":1733328048000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2827224"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.49017","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}